Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 1 DiabetesMedical DevicesIssue 607

Medtronic Remote Diabetes Monitor Gets U.S. Approval

Medtronic Inc. has announced it has received regulatory approval for the first remote glucose monitor that will let parents check the blood sugar of a diabetic child sleeping in another room....

Advertisement

About three out of four severe hypoglycemic reactions, in which a diabetic's blood sugar drops to a dangerously low level, occur overnight. Parents of children with diabetes typically get up several times a night to check whether the child's blood sugar is within healthy levels.

The bedside monitor, with an alarm that alerts the caregiver to blood glucose changes, helps protect against low blood sugar episodes, which can lead to seizures or even coma or death. Parents and other caregivers can see a child's or adult's glucose trends and insulin pump information on the device, called the mySentry Remote Glucose Monitor, and can take action to prevent a further decline in blood sugar if needed or remain in bed if all is well.

Britta Bushnell, whose 11-year-old son Kaden Kessel was diagnosed with type 1 diabetes when he was 2, is used to getting up during the night to check her child's blood sugar. She believes having a monitor could have prevented two low-glucose episodes that caused Kaden to temporarily lose the use of his limbs and ability to speak.

A suburban Los Angeles mother, Britta received a monitor last summer as part of Medtronic's evaluation process for the device. She stated that it gave her a peace of mind at night.

The mySentry monitor, which costs about $3,000, works with Medtronic's MiniMed Paradigm Real-Time Revel System, an insulin pump with built-in continuous glucose monitoring. In addition to displaying blood sugar readings, the device provides information on the insulin pump battery life and amount of insulin remaining.

Medtronic, a leading maker of insulin pumps and continuous glucose monitors, is among the companies and researchers working to develop an artificial pancreas system that ultimately would provide insulin dosing automatically.

Medtronic is also looking to develop monitoring technology that can one day work with consumer devices including mobile phones, Meehan said. "This is the first step in what we think is going to be a significant innovation category for diabetes care in the future," he said.

 
Medtronic
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 January, 2012 and appeared in  Type 1 DiabetesMedical DevicesIssue 607

Past five issues: Issue 777 | Diabetes Clinical Mastery Series Issue 236 | Issue 776 | Diabetes Clinical Mastery Series Issue 235 | Issue 775 |

2015 Most Popular Articles:

Glyburide Used for Gestational Diabetes May Increase Risk of Birth Complications
Posted April 02, 2015
A Potential New Type 2 Diabetes Indicator
Posted April 02, 2015
Women Retain Insulin Sensitivity Better than Men
Posted April 02, 2015
A Third Treatment Option in Uncontrolled Type 2 Diabetes
Posted April 02, 2015
A Novel Scale May Indicate Glycemic Progression to Type 1 Diabetes
Posted April 02, 2015
Gastric Electrical Stimulation an Alternative to Insulin Injections?
Posted April 02, 2015
Artificial Pancreas Software Algorithm Receives Approval in Europe
Posted April 02, 2015
Glycemic Control and Medications in T2DM Elderly with Dementia
Posted April 02, 2015
HbA1c and OGTT Performance in Prediabetic Obese Adolescents
Posted April 02, 2015
Type 2 Diabetes and Other Diseases Risk Related to Increase in Artificial Light?
Posted April 02, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you stop recommending the DPP-4s for your patients?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology
Search Articles On Diabetes In Control